Tomas Kalincik

List of Publications by Citations

143 papers	3,390 citations	32 h-index	54 g-index
162 ext. papers	4,403 ext. citations	6 avg, IF	5.25 L-index

#	Paper	IF	Citations
143	Defining secondary progressive multiple sclerosis. *Brain*, **2016**, 139, 2395-405	11.2	172
142	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. *JAMA - Journal of the American Medical Association*, **2019**, 321, 175-187	27.4	172
141	Treatment decisions in multiple sclerosis - insights from real-world observational studies. *Nature Reviews Neurology*, **2017**, 13, 105-118	15	126
140	Thalamic atrophy is associated with development of clinically definite multiple sclerosis. *Radiology*, **2013**, 268, 831-41	20.5	119
139	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. *Annals of Neurology*, **2015**, 77, 425-35	9.4	118
138	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. *Annals of Neurology*, **2016**, 80, 89-100	9.4	117
137	Fingolimod after natalizumab and the risk of short-term relapse. *Neurology*, **2014**, 82, 1204-11	6.5	113
136	Defining reliable disability outcomes in multiple sclerosis. *Brain*, **2015**, 138, 3287-98	11.2	107
135	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. *Lancet Neurology, The*, **2017**, 16, 271-281	24.1	101
134	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. *Brain*, **2013**, 136, 3609-17	11.2	96
133	Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). *Clinical Neuropsychologist*, **2012**, 26, 1186-200	4.4	88
132	Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. *JAMA Neurology*, **2015**, 72, 405-13	17.2	83
131	Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review. *Neuroepidemiology*, **2015**, 44, 199-214	5.4	79
130	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurology, The*, **2020**, 19, 307-316	24.1	77
129	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. *Autoimmunity Reviews*, **2017**, 16, 658-665	13.6	76
128	Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. *American Journal of Neuroradiology*, **2013**, 34, 1931-9	4.4	68
127	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. *Brain*, **2017**, 140, 2426-2443	11.2	62

126	Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. *PLoS ONE*, **2012**, 7, e50101	3.7	62
125	Observational data: Understanding the real MS world. *Multiple Sclerosis Journal*, **2016**, 22, 1642-1648	5	56
124	Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. *PLoS ONE*, **2013**, 8, e53996	3.7	50
123	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. *Neurology*, **2021**, 97, e1870-e1885	6.5	50
122	Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. *Lancet Neurology, The*, **2019**, 18, 973-980	24.1	49
121	Risk of relapse phenotype recurrence in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1511-22	5	49
120	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 458-468	5.5	46
119	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 196-203	5.5	43
118	Data quality evaluation for observational multiple sclerosis registries. *Multiple Sclerosis Journal*, **2017**, 23, 647-655	5	43
117	Comparative efficacy of switching to natalizumab in active multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2015**, 2, 373-87	5.3	42
116	Clinical correlates of grey matter pathology in multiple sclerosis. *BMC Neurology*, **2012**, 12, 10	3.1	41
115	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. *Journal of Neurology*, **2014**, 261, 1735-44	5.5	38
114	Predictors of disability worsening in clinically isolated syndrome. *Annals of Clinical and Translational Neurology*, **2015**, 2, 479-91	5.3	36
113	COVID-19 in people with multiple sclerosis: A global data sharing initiative. *Multiple Sclerosis Journal*, **2020**, 26, 1157-1162	5	34
112	Cost of multiple sclerosis in the Czech Republic: the COMS study. *Multiple Sclerosis Journal*, **2012**, 18, 662-8	5	32
111	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 51-61	5	31
110	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. *Neurology*, **2017**, 89, 1050-1059	6.5	31
109	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 520-32	5	30

108	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2015**, 21, 1159-71	5	30
107	Risk of secondary progressive multiple sclerosis: A longitudinal study. *Multiple Sclerosis Journal*, **2020**, 26, 79-90	5	27
106	Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study. *European Neurology*, **2012**, 68, 23-7	2.1	26
105	Olfactory ensheathing cells reduce duration of autonomic dysreflexia in rats with high spinal cord injury. *Autonomic Neuroscience: Basic and Clinical*, **2010**, 154, 20-9	2.4	23
104	Contribution of different relapse phenotypes to disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 266-276	5	22
103	Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β1a. *European Journal of Neurology*, **2015**, 22, 1113-23	6	22
102	Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. *PLoS ONE*, **2013**, 8, e63480	3.7	22
101	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. *Multiple Sclerosis and Related Disorders*, **2019**, 28, 235-243	4	22
100	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 1617-1626	5	21
99	Early predictors of non-response to interferon in multiple sclerosis. *Acta Neurologica Scandinavica*, **2012**, 126, 390-7	3.8	21
98	Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. *Neurology: Clinical Practice*, **2016**, 6, 102-115	1.7	21
97	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. *European Journal of Neurology*, **2017**, 24, 292-301	6	20
96	Associations of DMT therapies with COVID-19 severity in multiple sclerosis		20
95	The MSBase registry: Informing clinical practice. *Multiple Sclerosis Journal*, **2019**, 25, 1828-1834	5	19
94	Disturbance of real space navigation in moderately advanced but not in early Huntington's disease. *Journal of the Neurological Sciences*, **2012**, 312, 86-91	3.2	19
93	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. *Multiple Sclerosis Journal*, **2018**, 24, 642-652	5	18
92	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. *Neurology*, **2021**, 96, e783-e797	6.5	18
91	Cognitive clinico-radiological paradox in early stages of multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2018**, 5, 81-91	5.3	17

90	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. *Clinical Neurology and Neurosurgery*, **2012**, 114, 940-6	2	16
89	Monitoring of radiologic disease activity by serum neurofilaments in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	16
88	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. *Multiple Sclerosis and Related Disorders*, **2020**, 38, 101868	4	15
87	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. *Multiple Sclerosis Journal*, **2020**, 1352458520925369	5	14
86	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. *Genes and Immunity*, **2013**, 14, 244-8	4.4	14
85	Early clinical markers of aggressive multiple sclerosis. *Brain*, **2020**, 143, 1400-1413	11.2	13
84	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. *JAMA Neurology*, **2018**, 75, 1407-1415	17.2	13
83	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. *Neurology*, **2019**, 93, 793-800	9.5	13
82	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. *Multiple Sclerosis Journal*, **2017**, 23, 1346-1357	5	13
81	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. *Neurology: Clinical Practice*, **2020**, 10, 510-519	1.7	13
80	Serum microRNA is a biomarker for post-operative monitoring in glioma. *Journal of Neuro-Oncology* , **2020**, 149, 391-400	4.8	13
79	Familial mesial temporal lobe epilepsy and the borderland of dJ□vu. *Annals of Neurology*, **2017**, 82, 166-176	9.4	12
78	Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. *European Journal of Neurology*, **2015**, 22, 624-32	6	11
77	Selected changes in spinal cord morphology after T4 transection and olfactory ensheathing cell transplantation. *Autonomic Neuroscience: Basic and Clinical*, **2010**, 158, 31-8	2.4	11
76	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. *JAMA Neurology*, **2020**, 77, 1496-1503	17.2	11
75	Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis. *Frontiers in Neurology*, **2016**, 7, 206	4.1	10
74	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. *Multiple Sclerosis Journal*, **2021**, 27, 465-474	5	10
73	The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis. *Therapeutic Advances in Neurological Disorders*, **2019**, 12, 1756286419859183	6.6	9

72	Local response to cold in rat tail after spinal cord transection. *Journal of Applied Physiology*, **2009**, 106, 1976-85	3.7	9
71	Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. *Journal of Neurology*, **2019**, 266, 306-315	5.5	9
70	Heparinase-modified thromboelastography can result in a fibrinolytic pattern. *Anaesthesia*, **2010**, 65, 864-5	6.6	8
69	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. *JAMA Neurology*, **2020**, 77, 1398-1407	17.2	8
68	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. *Brain*, **2020**, 143, 2742-2756	11.2	8
67	Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. *Neurology*, **2021**,	6.5	8
66	Olfactory ensheathing cells but not fibroblasts reduce the duration of autonomic dysreflexia in spinal cord injured rats. *Autonomic Neuroscience: Basic and Clinical*, **2016**, 201, 17-23	2.4	8
65	Distinct psychopathology profiles in patients with epileptic seizures compared to non-epileptic psychogenic seizures. *Epilepsy Research*, **2019**, 158, 106234	3	8
64	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. *European Journal of Neurology*, **2019**, 26, 363-370	6	8
63	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. *Journal of Neuroimmunology*, **2021**, 357, 577627	3.5	8
62	Reporting treatment outcomes in observational data: A fine balance. *Multiple Sclerosis Journal*, **2017**, 23, 21-22	5	7
61	Arteriovenous differences of hematological and coagulation parameters in patients with sepsis. *Blood Coagulation and Fibrinolysis*, **2010**, 21, 770-4	1	7
60	Interferon-□or azathioprine as add-on therapies in patients with active multiple sclerosis. *Neurological Research*, **2012**, 34, 923-30	2.7	7
59	Discard volume necessary for elimination of heparin flush effect on thromboelastography. *Blood Coagulation and Fibrinolysis*, **2010**, 21, 192-5	1	7
58	Personality profiles differ between patients with epileptic seizures and patients with psychogenic non-epileptic seizures. *Seizure: the Journal of the British Epilepsy Association*, **2019**, 73, 1-8	3.2	6
57	Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic. *Multiple Sclerosis and Related Disorders*, **2021**, 47, 102642	4	6
56	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. *Multiple Sclerosis Journal*, **2020**, 26, 1765-1774	5	5
55	Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102516	4	5

54	Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study. *CNS Drugs*, **2021**, 35, 907-918	6.7	5
53	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms. *International Journal of Neuroscience*, **2021**, 131, 800-809	2	5
52	Psychometric properties of the Hospital Anxiety and Depression Scale in an inpatient video-monitoring epilepsy cohort. *Epilepsy and Behavior*, **2020**, 103, 106631	3.2	4
51	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. *Multiple Sclerosis Journal*, **2021**, 27, 695-705	5	4
50	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 556-562	5.5	4
49	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. *BMJ Open*, **2020**, 10, e040100	3	3
48	Presentation and outcome of patients with intracranial tuberculoma in a high HIV prevalence setting. *International Journal of Tuberculosis and Lung Disease*, **2020**, 24, 224-232	2.1	3
47	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	3
46	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. *Neurology*, **2021**, 97, e869-e880	6.5	3
45	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. *CNS Drugs*, **2021**, 35, 1097-1106	6.7	3
44	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 755-766	5	3
43	Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 1569-1577	5	3
42	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. *Multiple Sclerosis and Related Disorders*, **2021**, 53, 103012	4	3
41	Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial. *Trials*, **2020**, 21, 100	2.8	2
40	Abbreviated assessment of psychopathology in patients with suspected seizure disorders. *Epilepsy and Behavior*, **2019**, 100, 106530	3.2	2
39	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 2001-2013	5	2
38	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). *JMIR Research Protocols*, **2021**, 10, e24969	2	2
37	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. *Multiple Sclerosis Journal*, **2021**, 13524585211049986	5	2

36	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. *Neurology*, **2021**, 96, e214-e227	6.5	2
35	Lesser-Known Aspects of Deep Brain Stimulation for Parkinson's Disease: Programming Sessions, Hardware Surgeries, Residential Care Admissions, and Deaths. *Neuromodulation*, **2021**,	3.1	2
34	PACS Integration of Semiautomated Imaging Software Improves Day-to-Day MS Disease Activity Detection. *American Journal of Neuroradiology*, **2019**, 40, 1624-1629	4.4	2
33	Comparative effectiveness of rituximab in multiple sclerosis. *Nature Reviews Neurology*, **2021**, 17, 3-4	15	2
32	Determinants of therapeutic lag in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 1838-1851	5	2
31	Where there is inflammation, treatment may reduce disability progression - Yes. *Multiple Sclerosis Journal*, **2018**, 24, 1808-1810	5	2
30	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. *Computer Methods and Programs in Biomedicine*, **2021**, 208, 106180	6.9	2
29	Influence of magnesium sulphate on evoked activity of rat brain after exposure to short-term hypoxia. *Physiological Research*, **2005**, 54, 229-34	2.1	2
28	Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data. *Brain*, **2018**, 141, e39	11.2	1
27	Stop inflammation and you stop neurodegeneration in MS - NO. *Multiple Sclerosis Journal*, **2017**, 23, 1321-1323	5	1
26	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists.. *Multiple Sclerosis and Related Disorders*, **2022**, 57, 103389	4	1
25	Early clinical markers of aggressive multiple sclerosis		1
24	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities, and neuropsychiatric symptoms		1
23	Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years		1
22	Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes. *Multiple Sclerosis Journal*, **2020**, 26, 159-161	5	1
21	Adverse events related to antiepileptic drugs. *Epilepsy and Behavior*, **2021**, 115, 107657	3.2	1
20	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211035948	5	1
19	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. *CNS Drugs*, **2021**, 35, 1217-1232	6.7	1

18	Multiple Sclerosis Relapses Following Cessation of Fingolimod.. *Clinical Drug Investigation*, **2022**, 42, 355	3.2	1
17	Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study.. *Multiple Sclerosis and Related Disorders*, **2022**, 58, 103404	4	0
16	Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.. *Multiple Sclerosis and Related Disorders*, **2022**, 58, 103393	4	0
15	Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis. *Journal of Neuroimmunology*, **2021**, 353, 577508	3.5	0
14	020 Increased risk of an abnormal cervical screening test in women with MS exposed to high-efficacy disease-modifying treatments. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, A7.3-A7	5.5	0
13	The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 2055217321989767	2	0
12	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. *NeuroImage: Clinical*, **2021**, 32, 102802	5.3	0
11	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. *Neurology*, **2021**, 97, e2020-e2031	6.5	0
10	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. *Journal of the Neurological Sciences*, **2021**, 430, 118067	3.2	0
9	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.. *Multiple Sclerosis Journal*, **2022**, 13524585221084577	5	0
8	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy.. *Leukemia and Lymphoma*, **2022**, 1-11	1.9	0
7	A comparison of macular ganglion cell and retinal nerve fibre layer optical coherence tomographic parameters as predictors of visual outcomes of surgery for pituitary tumours.. *Pituitary*, **2022**, 1	4.3	0
6	The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2020**, 43, 102212	4	
5	The impact of location, time and practice effects on computerised cognitive testing using msreactor in people with multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, e1.3-e1	5.5	
4	Reply: Aggressive multiple sclerosis: a matter of measurement and timing. *Brain*, **2020**, 143, e98	11.2	
3	131 CLADIN: CLADribine and INnate immune responses. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, A42.3-A42	5.5	
2	The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis.. *Journal of Theoretical Biology*, **2022**, 541, 111091	2.3	
1	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.. *Pharmacoeconomics*, **2021**, 40, 323	4.4	